$3.07
0.33% today
Nasdaq, Feb 28, 09:18 pm CET
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

CureVac N.V. Target price 2025 - Analyst rating & recommendation

CureVac N.V. Classifications & Recommendation:

Buy
50%
Hold
33%
Sell
17%

CureVac N.V. Price Target

Target Price $6.77
Price $3.06
Potential
Number of Estimates 6
6 Analysts have issued a price target CureVac N.V. 2026 . The average CureVac N.V. target price is $6.77. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 6 analysts: 3 Analysts recommend CureVac N.V. to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the CureVac N.V. stock has an average upside potential 2026 of . Most analysts recommend the CureVac N.V. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 58.12 538.66
17.98% 826.81%
EBITDA Margin -473.92% 43.09%
23.15% 109.09%
Net Margin -490.21% 35.74%
12.20% 107.29%

6 Analysts have issued a sales forecast CureVac N.V. 2024 . The average CureVac N.V. sales estimate is

$539m
Unlock
. This is
9.59% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$565m 5.23%
Unlock
, the lowest is
$475m 20.31%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $58.1m 17.98%
2024
$539m 826.81%
Unlock
2025
$67.1m 87.54%
Unlock
2026
$139m 107.85%
Unlock
2027
$154m 10.31%
Unlock

4 Analysts have issued an CureVac N.V. EBITDA forecast 2024. The average CureVac N.V. EBITDA estimate is

$232m
Unlock
. This is
12.52% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$280m 35.49%
Unlock
, the lowest is
$206m 0.11%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-275m 1.00%
2024
$232m 184.28%
Unlock
2025
$-107m 146.16%
Unlock
2026
$-74.8m 30.16%
Unlock
2027
$-33.8m 54.85%
Unlock

EBITDA Margin

2023 -473.92% 23.15%
2024
43.09% 109.09%
Unlock
2025
-159.67% 470.55%
Unlock
2026
-53.65% 66.40%
Unlock
2027
-21.96% 59.07%
Unlock

3 CureVac N.V. Analysts have issued a net profit forecast 2024. The average CureVac N.V. net profit estimate is

$193m
Unlock
. This is
56.05% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$267m 116.72%
Unlock
, the lowest is
$142m 15.31%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-285m 7.97%
2024
$193m 167.58%
Unlock
2025
$-118m 161.36%
Unlock
2026
$-66.0m 44.18%
Unlock
2027
$-84.0m 27.32%
Unlock

Net Margin

2023 -490.21% 12.20%
2024
35.74% 107.29%
Unlock
2025
-176.03% 592.53%
Unlock
2026
-47.28% 73.14%
Unlock
2027
-54.57% 15.42%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.27 0.86
7.97% 167.72%
P/E 3.57
EV/Sales 0.22

3 Analysts have issued a CureVac N.V. forecast for earnings per share. The average CureVac N.V. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$0.86
Unlock
. This is
56.36% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$1.19 116.36%
Unlock
, the lowest is
$0.63 14.55%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.27 7.97%
2024
$0.86 167.72%
Unlock
2025
$-0.53 161.63%
Unlock
2026
$-0.29 45.28%
Unlock
2027
$-0.37 27.59%
Unlock

P/E ratio

Current 5.57 357.87%
2024
3.57 35.91%
Unlock
2025
-5.81 262.75%
Unlock
2026
-10.41 79.17%
Unlock
2027
-8.18 21.42%
Unlock

Based on analysts' sales estimates for 2024, the CureVac N.V. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.20 96.87%
2024
0.22 8.00%
Unlock
2025
1.73 702.78%
Unlock
2026
0.83 51.89%
Unlock
2027
0.76 9.34%
Unlock

P/S ratio

Current 1.15 92.87%
2024
1.27 10.61%
Unlock
2025
10.23 702.67%
Unlock
2026
4.92 51.89%
Unlock
2027
4.46 9.35%
Unlock

Current CureVac N.V. Upgrades & Downgrades Beta

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JMP Securities Locked ➜ Locked Locked Feb 14 2025
JMP Securities Locked ➜ Locked Locked Sep 16 2024
Analyst Rating Date
Locked
JMP Securities: Locked ➜ Locked
Feb 14 2025
Locked
JMP Securities: Locked ➜ Locked
Sep 16 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today